Biotechnology BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers June 27, 2022
Biotechnology ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important July 12 Deadline in Securities Class Action – AXSM June 25, 2022
Biotechnology Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron June 25, 2022
Biotechnology ROSEN, A TOP RANKED FIRM, Encourages Axsome Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM June 24, 2022
Search
Biotechnology
